Similar results have been obtained for rutin; oral administration to mice with the CD4+ CD62L+ T cell-induced colitis model, which is closer to the human IBD compared to chemically induced colitis, led to improvement of colitis symptoms and a marked reduction in colonic levels of myeloperoxidase (MPO), an ROS-producing enzyme. Here, MPO is linked to inflammatory bowel disease.